Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Moodys
McKinsey
Mallinckrodt

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,034,902


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,034,902 protect, and when does it expire?

Patent 9,034,902 protects JORNAY PM and is included in one NDA.

This patent has thirty patent family members in fourteen countries.

Summary for Patent: 9,034,902
Title:Methods for treatment of attention deficit hyperactivity disorder
Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Inventor(s): Lickrish; David (Grand Cayman, KY), Zhang; Feng (Pflugerville, TX)
Assignee: Ironshore Pharmaceuticals & Development, Inc. (Camana Bay, KY)
Application Number:14/577,963
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,034,902

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-001 Aug 8, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try it Free
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-002 Aug 8, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try it Free
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-003 Aug 8, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try it Free
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-004 Aug 8, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try it Free
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-005 Aug 8, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,034,902

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012230733 ⤷  Try it Free
Australia 2016228307 ⤷  Try it Free
Australia 2018202002 ⤷  Try it Free
Brazil 112013024401 ⤷  Try it Free
Canada 2830788 ⤷  Try it Free
China 103608004 ⤷  Try it Free
China 110151731 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Boehringer Ingelheim
Colorcon
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.